Back to top

Citi Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX)

Citi analyst Geoff Meacham maintained a Buy rating on Vertex Pharmaceuticals on October 10 and set a price target of $575.00. The company’s shares ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Vertex Pharmaceuticals Incorporated (VRTX)